There are currently 148 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Non-Small Cell Lung Cancer participants are California, Texas, Florida and New York.
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
NCT04982926
Recruiting
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: Tennessee Oncology, Nashville, Tennessee +2 locations
Conditions: Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
Register for Updates
KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC
NCT05254184
Recruiting
This is a single institution, Phase 1 study for patients with Stage III/IV unresectable Kirsten rat sarcoma (KRAS) mutated NSCLC to evaluate safety of the pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with polyinosinic-polycytidylic acid (poly-ICLC) adjuvant in combination with nivolumab and ipilimumab in the first line treatment setting. The primary objectives of this study are to determine the safety and feasibility of administering the KRAS peptide vaccine with poly-ICLC adjuvant... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
01/23/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC
NCT04093167
Recruiting
BR36 will evaluate the potential clinical benefit of tailoring immunotherapy treatment based on ctDNA molecular response in non-small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: The Sidney Kimmel Comprehensive Cancer Centre, Baltimore, Maryland +5 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Investigate LYL845 in Adults With Solid Tumors
NCT05573035
Recruiting
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2024
Locations: UC Davis Coomprehensive Cancer Center, Sacramento, California +14 locations
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Register for Updates
Study to Evaluate CCS1477 in Advanced Tumours
NCT03568656
Recruiting
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +21 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer, Advanced Solid Tumors, Metastatic Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
NCT06083454
Recruiting
This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: Non-small Cell Lung Cancer
Register for Updates
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
NCT04878952
Recruiting
This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: WellSpan Health - Chambersburg, Chambersburg, Pennsylvania +4 locations
Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
Register for Updates
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer
NCT01817192
Recruiting
The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed surgically from the lung, and this standard has been based on the fact that no previous clinical trial has demonstrated a benefit for Stage I or Stage IIA NSCLC patients who receive post-operative chemotherapy. These patients, however, have a substantial risk of death within five... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Highlands Oncology Group, Springdale, Arkansas +50 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
NCT05254795
Recruiting
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
12/07/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of TAS3351 in NSCLC Patients With EGFRmt
NCT05765734
Recruiting
This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia +16 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
NCT05737706
Recruiting
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Mayo Clinic Hospital, Phoenix, Arizona +13 locations
Conditions: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Register for Updates
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384
Recruiting
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Orchard Healthcare Research Inc., Skokie, Illinois
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Register for Updates